Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388106 | 0.88 | TSHR (0.53) | TSHRFFAR4LMNAGAASMN1; SMN2 | |
| SCHEMBL5159892 | 0.86 | FFAR4 (0.74) | TSHRFFAR4LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5101148 | 0.83 | FFAR4 (0.69) | TSHRFFAR4LMNAGAAALDH1A1 | |
| SCHEMBL13999327 | 0.81 | ELANE (0.63) | TSHRFFAR4LMNAGAASMN1; SMN2 | |
| SCHEMBL5788749 | 0.80 | TSHR (0.51) | TSHRFFAR4LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL28660013 | 0.78 | KMT2A (0.62) | TSHRFFAR4LMNAGAASMN1; SMN2 | |
| SCHEMBL7146905 | 0.77 | ALDH1A1 (0.57) | TSHRFFAR4LMNAGAAALDH1A1 | |
| SCHEMBL7322545 | 0.76 | FFAR4 (0.65) | TSHRFFAR4LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7322031 | 0.76 | FFAR4 (0.74) | FFAR4LMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5089669 | 0.75 | MMP13 (0.53) | TSHRGAAALDH1A1HTTADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470794-B2 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825352-B2 | ANTIARTHRITIC, ANTITUMOR, ANTIMETASTASIS, ANTIULCER, AND WOUND HEALING AGENTS; BONE, NERVOUS SYSTEM, DEGENERATIVE JOINT DISORDERS; PROTEINURIA, ANEURYSMS, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | disclosed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | disclosed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP7, MMP2 | TSHR 2628/4885FFAR4 4578/4885LMNA 1673/4885 |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | MMP1, MMP7, MMP2 | TSHR 2628/4885FFAR4 4578/4885LMNA 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.